THE High Court has dismissed an application for special leave to appeal by the Australian Competition & Consumer Commission (ACCC) in its case against Pfizer over pharmacy rebates on Lipitor (PD 08 Oct 2014).
The Full Federal Court ruled earlier this year against the ACCC (PD 28 May 2018) which had accused Pfizer of misusing its market power and attemping to substantially lessen competition in the market for atorvastatin.
The above article was sent to subscribers in Pharmacy Daily's issue from 22 Oct 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 22 Oct 18
